Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris
- D. Pathirana, A. Ormerod, B. Rzany
- MedicineJournal of the European Academy of Dermatology…
- 1 October 2009
Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris and has a good cost-benefit ratio, but the potentially significant costs for, and time required of, the patient must be considered.
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoriasis.
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Bdalumab significantly improved plaque psoriasis in this 12-week, phase 2 study and was superior to placebo in all comparisons.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways
The results provide strong support for the association of at least seven genetic loci and psoriasis (each with combined P < 5 × 10−8) and suggest priority targets for study in other auto-immune disorders.
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis.